ARTICLE | Company News
Biovail, Prestwick deal
September 22, 2008 7:00 AM UTC
Biovail bought Prestwick for $100 million in cash. The deal gives Biovail Canadian rights to Nitoman tetrabenazine to treat hyperkinetic movement disorders. Prestwick had U.S. and Canadian rights to ...